Роль дигидропиридиновых антагонистов кальция в лечении сердечно-сосудистых заболеваний: фокус на амлодипин

1. Рекомендации РМОАГ/ВНОК по диагностике и лечению артериальной гипертонии 2013.
2. Mancia G, Fagard R, Narkiewicz K et al. Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2013; 31: 1925–38.
3. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311 (5): 507–20.
4. Angeli F et al. Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens 2004; 17 (9): 817–22.
5. Toyo-Oka T, Nayler WG. Third generation calciumentry blockers. Blood Press 1996; 5: 206–8.
6. Leenen FH et al. Persistence of antihypertensive effect after missed doses of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life. British J Clin Pharmacol 1996; 41 (2): 83–8.
7. Levine CB, Fahrbach KR, Frame D et al. Effect of amlodipine on systolic blood pressure. Clin Therapeutics 2003; 25: 35–57.
8. Kloner R, Sowers L, DiBona G et al. Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial study group. Am J Cardiol 1996; 77 (9): 713–22.
9. Meredith PA. Role of through to peak efficacy in the evaluation of antihypertensive efficacy. J Hypertension 1998; 16 (Suppl. 1): S59–S64.
10. Picca M, Bisceglia J, Zocca A, Pelosi G. Effects of enalapril and amlodipine on left ventricular hypertrophy and function in essential hypertension. Clin Drug Invest 1997; 13 (Suppl. 1): 29–35.
11. Zanchetti A, Ruilope LM, Cuspidi C et al. Comparative effects of the ACE inhibitor fosinopril and the calcium antagonist amlodipine on left ventricular hypertrophy and urinary albumin excretion in hypertensive patients. Results of FOAM, a multicenter European study. J Hypertens 2001; 19 (Suppl. 2): S92.
12. Mancini GBJ, Miller ME, Evans GW et al. Post hoc analysis of coronary findings from the Prospective Randomized Evaluation of the Vascular Effects of the Norvasc Trial (PREVENT). Am J Cardiol 2002; 89 (12): 1414–6.
13. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967–75.
14. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipin: the VALUE randomized trial. Lancet 2004; 363 (9426): 2022–3.
15. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an Antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofluazide as required, in Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
16. Sever PS, Dahlof B, Poultier NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): multicentre randomised controlled trial. Lancet 2003; 361: 1149–58.
17. Sever PS, Dahlof B, Poultier NR et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006; 27: 2982–8.
18. Davis RF, Habibi H, Klinke WP et al. Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. JACC 1995; 25: 619–25.
19. Deanfield J, Detry J, Sellier P et al. Medical treatment of myocardial ischemia in coronary heart disease: Effect of drug regimen and irregular dosing in CAPE II trial. JACC 2002; 40 (5): 917–25.
20. Pitt B, Byington R, Furberg C et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503–10.
21. Nissen S, Tuzcu E, Libby P et al. Effects of antihypertensive drugs on cardiovascular events in patients with coronary heart disease and normal blood pressure. Randomized controlled CAMELOT study. JAMA 2004; 292 (18): 2217–26.
22. Jorgensen B, Thaulow E. Effects of amlodipine on ischemia after percutaneuostransluminal coronary angioplasty: Secondary results of the Coronary Angioplasty Amlodipine Restenosis (CAPARES) study. Am Heart J 2003; 145: 1030–5.

Г.А.Барышникова, С.А.Чорбинская

ФГБУ Учебно-научный медицинский центр Управления делами Президента РФ, Москва